http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 27 Jan 2026 14:06:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Business+Wire/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 +0000 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html <div class="xn-content"> <p>- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit<br />- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy<br />- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>Dec. 7, 2025</chron></span> /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html Sun, 07 Dec 2025 12:01:00 +0000 A.32437804 A.36355542 A.60012004 CSL CSLLY O.00162576 O.00673957 O.00832571 O.01304637 O.13165654 QURE http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html <div class="xn-content"> <p>- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit<br />- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy<br />- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>Dec. 7, 2025</chron></span> /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html Sun, 07 Dec 2025 12:01:00 +0000 A.32437804 A.36355542 A.60012004 CSL CSLLY O.00162576 O.00673957 O.00832571 O.01304637 O.13165654 QURE http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html <div class="xn-content"> <p>- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit<br />- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy<br />- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>Dec. 7, 2025</chron></span> /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html Sun, 07 Dec 2025 12:01:00 +0000 A.32437804 A.36355542 A.60012004 CSL CSLLY O.00162576 O.00673957 O.00832571 O.01304637 O.13165654 QURE http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html <div class="xn-content"> <p>- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit<br />- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy<br />- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>Dec. 7, 2025</chron></span> /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html Sun, 07 Dec 2025 12:01:00 +0000 A.32437804 A.36355542 A.60012004 CSL CSLLY O.00162576 O.00673957 O.00832571 O.01304637 O.13165654 QURE http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html <div class="xn-content"> <p>- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit<br />- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy<br />- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>Dec. 7, 2025</chron></span> /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html Sun, 07 Dec 2025 12:01:00 +0000 A.32437804 A.36355542 A.60012004 CSL CSLLY O.00162576 O.00673957 O.00832571 O.01304637 O.13165654 QURE http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html <div class="xn-content"> <p>- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit<br />- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy<br />- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>Dec. 7, 2025</chron></span> /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html Sun, 07 Dec 2025 12:01:00 +0000 A.32437804 A.36355542 A.60012004 CSL CSLLY O.00162576 O.00673957 O.00832571 O.01304637 O.13165654 QURE http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html <div class="xn-content"> <p>- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit<br />- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy<br />- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>Dec. 7, 2025</chron></span> /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html Sun, 07 Dec 2025 12:01:00 +0000 A.32437804 A.36355542 A.60012004 CSL CSLLY O.00162576 O.00673957 O.00832571 O.01304637 O.13165654 QURE http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html <div class="xn-content"> <p>- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit<br />- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy<br />- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>Dec. 7, 2025</chron></span> /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html Sun, 07 Dec 2025 12:01:00 +0000 A.32437804 A.36355542 A.60012004 CSL CSLLY O.00162576 O.00673957 O.00832571 O.01304637 O.13165654 QURE http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html <div class="xn-content"> <p>- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic benefit<br />- At year five, mean factor IX activity levels remained strong at 36.1% and HEMGENIX continued to demonstrate a favorable safety profile, reinforcing its durable efficacy<br />- More than 75 individuals across eight countries have received HEMGENIX in real-world settings, reflecting growing global adoption</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>Dec. 7, 2025</chron></span> /PRNewswire/ -- Global biopharma leader CSL (ASX:CSL; USOTC:CSLLY) today announced five-year (60-month) results from the pivotal Phase 3 http://www.streetinsider.com/Press+Releases/Data+Published+in+the+New+England+Journal+of+Medicine+Confirm+the+Long-term+Durability+and+Safety+of+HEMGENIX%C2%AE+%28etranacogene+dezaparvovec-drlb%29+Over+Five+Years/25708066.html Sun, 07 Dec 2025 12:01:00 +0000 A.32437804 A.36355542 A.60012004 CSL CSLLY O.00162576 O.00673957 O.00832571 O.01304637 O.13165654 QURE